Active Ingredient History
Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cholangiocarcinoma (Phase 3)
Colitis, Ulcerative (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Leukemia, Myeloid, Acute (Phase 1)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 2)
Receptors, Fibroblast Growth Factor (Phase 2)
Stomach Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
